Intralipid–Its rational use in parenteral nutrition of the newborn

Publisher Website
Google Scholar
Abstract
The recent release of Intralipid by the FDA has made available a calorie-dense and nutritious supplement to parenteral feeding regimens. Since it was first developed and introduced in 1961 by Wretlind and co-workers in Sweden, a large and successful experience has accrued in Europe and Canada in patients with burns, severe malnutrition, gastrointestinal disorders, and anomalies. It has not, however, been widely used in newborn infants. In general, complications are rare and anaphylactic reactions experienced with the use of earlier intravenous fat emulsions are not seen.1 Intralipid is a 10% emulsion of soybean oil stabilized with 1.2% egg phospholipid with a particle size less than 1 mµ and metabolic fate similar to naturally occurring chylomicrons.